U001 Alopecia Areata Power Hour
DESCRIPTION
Alopecia areata is commonly encountered by dermatologists in clinical practice. While the diagnosis is typically straightforward, treatment can be challenging. This session will provide an overview of the diagnosis and management of alopecia areata, including recent progress in scientific understanding and therapeutics. We will review factors to consider when assessing disease severity and making treatment decisions and explore a range of available therapeutic options.
LEARNING OBJECTIVES
Recognize the psychosocial impact of alopecia areata and clinical factors that influence disease severity
Outline therapeutic options for alopecia areata
Describe the role of Janus kinase inhibitors for the treatment of alopecia areata
SCHEDULE
7:30 AM
Alopecia Areata Power Hour
Brittany Craiglow, MD, FAAD
DIRECTOR
Brittany Craiglow, MD, FAAD
DISCLOSURES
Brittany Craiglow, MD, FAAD
AbbVie – Consultant (1099 relationship)(Fees), Speaker(Honoraria); Arcutis Biotherapeutics – Consultant (1099 relationship)(Fees), Speaker(Fees); BiologicsMD, Inc. – Consultant (1099 relationship)(Fees); Concert Pharmaceuticals – Consultant(Grants/Research Funding); CorEvitas – Consultant (1099 relationship)(Fees); Dermavant Sciences, Inc. – Advisory Board(Fees); Eli Lilly and Company – Advisory Board(Fees), Consultant(Fees), Speaker(Honoraria); GlaxoSmithKline Immunology – Consultant (1099 relationship)(Fees); Incyte – Advisory Board(Fees); Incyte Corporation – Speaker(Honoraria); Leo Pharma – Advisory Board(Fees); Novartis – Advisory Board(Fees); Pfizer Inc. – Advisory Board(Fees), Consultant(Fees), Investigator(No Compensation Received), Speaker(Honoraria); Regeneron Pharmaceuticals, Inc. – Advisory Board(Fees), Consultant (1099 relationship)(Fees), Speaker(Honoraria); Sanofi Genzyme – Speaker(Honoraria); Sun Pharmaceutical Industries Ltd. – Advisory Board(Fees); Takeda Pharmaceuticals USA Inc – Advisory Board(Fees);